Built for speed. Designed for depth.
Mirador360™ brings data, science and strategy together in one engine—anchored by three principles:
Precision-first by design
Data, analytics and biology don’t sit in silos. They work together by design.
Dynamic and learning
Every iteration strengthens the system. New data expands capability and confidence.
Built for real-world delivery
Insights translate directly into pipeline decisions, including differentiated targets, optimal combinations and precision-driven clinical strategies.
From complexity to clarity. Insight to impact.
Mirador360™ enables a quantum leap in precision medicine by harnessing cutting-edge biology, multi-modal data and advanced analytics to develop precision therapies. Scroll to see how it comes together.
Multi-modal data
Mirador360™ houses one of the most extensive repositories of immune-mediated disease data and is continually expanding. Our comprehensive database of curated, harmonized, high-quality public and private data, with integrated multiomics and clinical data, is the foundation of our engine.
Advanced analytics and AI-driven discovery
Advanced analytics, proprietary AI/ML models and supercharged deep-learning algorithms unlock hidden value from our database to deliver novel insights that inform smarter drug design.
Precision insights
The current landscape of immune-mediated disease therapies faces a critical challenge: limited target differentiation. Mirador360™ is built to break the efficacy ceiling and identify innovative therapeutic targets with greater degree of confidence. Mirador360™ insights enable smarter drug design, targeted drug combinations and multispecifics, indication selection and diagnostic development to identify patients most likely to benefit.
Pipeline of first- & best-in-class therapies
The result: first- and best-in-class therapies with higher probability of success and accelerated paths to clinic and market.
A foundation for the future, engineered to scale
As we expand our pipeline, Mirador360™ continues to evolve—fueling discovery across a range of immuno-fibrotic conditions. It’s not locked in a lab. It’s built to adapt.
This isn’t just how we work. It's how we deliver what's next in immunology.